Drugs News and Research

RSS

Jasmine can be used instead of sleeping pills or mood enhancers: Study

Instead of a sleeping pill or a mood enhancer, a nose full of jasmine from Gardenia jasminoides could also help: in collaboration with Dr. Olga Sergeeva and Prof. Helmut Hass from the Heinrich Heine University in Düsseldorf, researchers from Bochum led by Prof. Dr. Dr. Dr. Hanns Hatt have discovered that the two fragrances Vertacetal-coeur (VC) and the chemical variation (PI24513) have the same molecular mechanism of action and are as strong as the commonly prescribed barbiturates or propofol.

9 Jul 2010

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.

9 Jul 2010

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

The U.S. Food and Drug Administration today warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks.

9 Jul 2010

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, and Intellikine, Inc., a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, today announced an agreement under which Infinity obtained global development and commercialization rights to Intellikine's portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase.

8 Jul 2010

pSivida submits MAA for Iluvien to UK MHRA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.

8 Jul 2010

Calithera Biosciences completes Series A financing totaling $40M

Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.

8 Jul 2010

WSBI, University of Colorado sign licensing agreement for TCISM targets

Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.

8 Jul 2010

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza™ that support its use in a hospital setting.

8 Jul 2010

Biopharmaceutical Nanotechnology Scientific Forum to take place in Philadelphia between August 16-18

IQPC presents Biopharmaceutical Nanotechnology Scientific Forum taking place August 16-18 in Philadelphia, PA.

From IQPC Ltd 8 Jul 2010

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

AHF denounces Obama administration plan to address AIDS drug crisis with $25M

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, will host a press teleconference tomorrow, Thursday, July 8th at 10:00 AM Pacific/1:00 PM Eastern, to denounce an Obama administration plan to address AIDS drug crisis with an insufficient $25 million as "too little, too late."

8 Jul 2010

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Selvita sp. z o.o., from Krakow, Poland and Orion Corporation from Espoo, Finland (ORNBV) today announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita's proprietary program for the treatment of Alzheimer's disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

8 Jul 2010

PolyMAC technique retrieves specific proteins needed to study formation of cancer cells

A Purdue University researcher can better retrieve specific proteins needed to study how cancer cells form by using a newly developed technique and synthetic nanopolymer.

8 Jul 2010

UTHealth Biotechnology Commercialization Center leases over three-quarters of available space

The University of Texas Health Science Center at Houston (UTHealth) announced that its Biotechnology Commercialization Center (BCC) has leased more than three-quarters of its available space to eight Texas-based startups in less than a year. The center's focus is to assist biotech entrepreneurs and small companies with the translation of discoveries into innovative health solutions.

8 Jul 2010

Optics Express publishes special focus issue on lung cancer imaging research

Advanced imaging technologies that promise to improve the development of effective drugs to treat lung cancer are the focus of the current special issue of Optics Express, an open-access journal published by the Optical Society (OSA). Research featured in the special focus issue on Imaging in Diagnosis and Treatment of Lung Cancer outlines standardized approaches to measure and compare tumor size, as well as to validate the accuracy of such measurements under defined settings.

8 Jul 2010

Research findings link some autoimmune disorders with cancer

Patients with a certain type of scleroderma may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.

8 Jul 2010

Local anesthetics have potential therapeutic effects on IBD: Research article

Inflammatory bowel disease is a disease of the gastrointestinal tract, mainly the intestines that may occur in the people who have genetic potential with a contribution of environmental factors. There has been no definitive medical treatment and drugs usually help the symptoms just to relieve.

8 Jul 2010

TB Alliance, DNDi announce inter-PDP agreement to develop potential anti-TB compounds

The Global Alliance for TB Drug Development and Drugs for Neglected Diseases initiative announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world's poor.

8 Jul 2010

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

Nymox Pharmaceutical Corporation reported today positive new results from pooled analysis of completed clinical trials of NX-1207, the Company's investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptom of urgent need to urinate.

8 Jul 2010

Report shows more than one way to get rid of cholesterol

Many of us are simply overloaded with cholesterol, and now a report in the July issue of Cell Metabolism brings what might be good news: There is more than one way to get rid of that cholesterol, which can otherwise lead to atherosclerosis and heart disease.

8 Jul 2010

Drugs News and Research

Jasmine can be used instead of sleeping pills or mood enhancers: Study

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

pSivida submits MAA for Iluvien to UK MHRA

Calithera Biosciences completes Series A financing totaling $40M

WSBI, University of Colorado sign licensing agreement for TCISM targets

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Biopharmaceutical Nanotechnology Scientific Forum to take place in Philadelphia between August 16-18

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

AHF denounces Obama administration plan to address AIDS drug crisis with $25M

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

PolyMAC technique retrieves specific proteins needed to study formation of cancer cells

UTHealth Biotechnology Commercialization Center leases over three-quarters of available space

Optics Express publishes special focus issue on lung cancer imaging research

Research findings link some autoimmune disorders with cancer

Local anesthetics have potential therapeutic effects on IBD: Research article

TB Alliance, DNDi announce inter-PDP agreement to develop potential anti-TB compounds

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

Report shows more than one way to get rid of cholesterol

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News